AML and MDS associated with PARP inhibitor treatment of ovarian cancer

被引：4

作者：

Armstrong, Deborah K. ^{[1
]}

机构：

[1] Johns Hopkins Kimmel Canc Ctr, Skip Viragh Outpatient Canc Bldg,201 N Broadway,Ro, Baltimore, MD 21287 USA

来源：

GYNECOLOGIC ONCOLOGY | 2023年 / 171卷

关键词：

OLAPARIB;

D O I：

10.1016/j.ygyno.2022.11.027

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：162 / 163

页数：2

相关论文

共 20 条

[1]

[Anonymous], 2022, GSK HLTH CARE PROVID

[2]

CIK, CLOVIS SEC FILING

[3]

CIK, CLOVIS SEC FILING 12

[4]

clovisoncology, CLOVIS HLTH CARE PRO

[5]

Coleman R.L., 2022, 2022 IGCS ANN M

[6] Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial [J].

DiSilvestro, Paul ;

Banerjee, Susana ;

Colombo, Nicoletta ;

Scambia, Giovanni ;

Kim, Byoung-Gie ;

Oaknin, Ana ;

Friedlander, Michael ;

Lisyanskaya, Alla ;

Floquet, Anne ;

Leary, Alexandra ;

Sonke, Gabe S. ;

Gourley, Charlie ;

Oza, Amit ;

Gonzalez-Martin, Antonio ;

Aghajanian, Carol ;

Bradley, William ;

Mathews, Cara ;

Liu, Joyce ;

McNamara, John ;

Lowe, Elizabeth S. ;

Ah-See, Mei-Lin ;

Moore, Kathleen N. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) :609-+

[7] Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer [J].

Gonzalez-Martin, A. ;

Pothuri, B. ;

Vergote, I. ;

DePont Christensen, R. ;

Graybill, W. ;

Mirza, M. R. ;

McCormick, C. ;

Lorusso, D. ;

Hoskins, P. ;

Freyer, G. ;

Baumann, K. ;

Jardon, K. ;

Redondo, A. ;

Moore, R. G. ;

Vulsteke, C. ;

O'Cearbhaill, R. E. ;

Lund, B. ;

Backes, F. ;

Barretina-Ginesta, P. ;

Haggerty, A. F. ;

Rubio-Perez, M. J. ;

Shahin, M. S. ;

Mangili, G. ;

Bradley, W. H. ;

Bruchim, I. ;

Sun, K. ;

Malinowska, I. A. ;

Li, Y. ;

Gupta, D. ;

Monk, B. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) :2391-2402

[8] Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial [J].

Kristeleit, Rebecca ;

Lisyanskaya, Alla ;

Fedenko, Alexander ;

Dvorkin, Mikhail ;

de Melo, Andreia Cristina ;

Shparyk, Yaroslav ;

Rakhmatullina, Irina ;

Bondarenko, Igor ;

Colombo, Nicoletta ;

Svintsitskiy, Valentyn ;

Biela, Luciano ;

Nechaeva, Marina ;

Lorusso, Domenica ;

Scambia, Giovanni ;

Cibula, David ;

Poka, Robert ;

Oaknin, Ana ;

Safra, Tamar ;

Mackowiak-Matejczyk, Beata ;

Ma, Ling ;

Thomas, Daleen ;

Lin, Kevin K. ;

McLachlan, Karen ;

Goble, Sandra ;

Oza, Amit M. .

LANCET ONCOLOGY, 2022, 23 (04) :465-478

[9]

lynparzahcp, ASTRA ZENECA HLTH CA

[10] Poly(ADP-ribose) polymerase inhibitor-associated myelodysplastic syndrome/acute myeloid leukemia: a pharmacovigilance analysis of the FAERS database [J].

Ma, Z. ;

Sun, X. M. ;

Lu, W. C. ;

Zhao, Z. X. ;

Xu, Z. M. ;

Lyu, J. Y. ;

Zhao, P. ;

Liu, L. H. .

ESMO OPEN, 2021, 6 (01)